KDM1A Promotes Immunosuppression in Hepatocellular Carcinoma by Regulating PD-L1 through Demethylating MEF2D

BACKGROUND: Immune checkpoint inhibitor therapy targeting antiprogrammed cell death-1 (anti-PD-1) or its ligand (anti-PD-L1) is effective in the treatment of some hepatocellular carcinomas (HCC). Hence, further identification of biological targets related to PD-L1 regulation in HCC is beneficial to...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yonglan, Cao, Kun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270703/
https://www.ncbi.nlm.nih.gov/pubmed/34307695
http://dx.doi.org/10.1155/2021/9965099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270703/
https://www.ncbi.nlm.nih.gov/pubmed/34307695
http://dx.doi.org/10.1155/2021/9965099

Ejemplares similares